Finally, in one of our clinical studies, we evaluated the safety and tolerability of combining an anti-TNF agent, either infliximab or certolizumab, with anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab) antibodies in advanced melanoma patients. Here, CTLA4 is linked to melanoma.